Patents
Literature
50 results about "Bisacodyl" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Bisacodyl is used to treat constipation. It may also be used to clean out the intestines before a bowel examination/surgery.
Method of bowel cleansing
InactiveUS7291324B2Lower the volumeSafe and effectiveDigestive systemPharmaceutical delivery mechanismIntestinal structureBowel cleansing
Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic ravages, or smaller volume hypertonic lavages.
Owner:BRAINTREE LAB
Method of bowel cleansing
InactiveUS20070298008A1Lower the volumeSafe and effectiveDigestive systemSynthetic polymeric active ingredientsIntestinal structureBowel cleansing
Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic lavages, or smaller volume hypertonic lavages.
Owner:BRAINTREE LAB
Method for preparing high purity sodium picosulfate
InactiveCN103086957AAvoid formingThe reaction mechanism is simple and singleOrganic chemistryBisacodylHydrolysis
The invention relates to a method for preparing high purity sodium picosulfate. The method is characterized in that based on bisacodyl as the starting material, sodium picosulfate is prepared by hydrolysis reaction and sulphating reaction. The preparation method is simple in process flow, simple and convenient to operate, and suitable for industrial production. The sodium picosulfate prepared is high in purity and meets the quality standard required by European and United States Pharmacopeia.
Owner:SHANDONG INST OF PHARMA IND
Preparation method of bisacodyl
The invention relates to a preparation method of bisacodyl, which comprises the following steps of: by adopting sulphuric acid as a catalyst, carrying out condensation reaction on 2-pyridylaldehyde and phenol at 0-15 DEG C; regulating pH to be 7.0 by using 2mol / L sodium hydroxide; stirring for 2 hours; then, adding ethyl acetate and filtering to obtain 4',4''-dihydroxydiphenyl-(2- pyridine)-methane; adding the 4',4''-dihydroxydiphenyl-(2-pyridine)-methane, methylene dichloride and 2mol / L sodium hydroxide; adding 4-dimethylamino pyridine (DMAP) as a catalyst; then, adding acetic anhydride for reaction for 0.5 hour at room temperature; concentrating and drying to obtain crude products of bisacodyl; and recrystallizing the crude products of the bisacodyl with ethanol to obtain high-purity bisacodyl. The method has the advantages that the process is simple and can be easily operated, the product yield is high and can reach 61 percent after the purification, the purity of the bisacodyl is high with the content is 99 percent, the phenol can be recovered so taht the resource waste is avoided and the environment production is alleviated, and the production cost is low.
Owner:HEBEI KANGTAI PHARMA
Composition for improving treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient and preparation method thereof
InactiveCN105495150AImprove securityConstipation Treatment EnhancementBacteriaDigestive systemSide effectFeces
The invention relates to a composition for improving treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient and a preparation method thereof. The Cassia fermented by lactic acid bacteria can used for a long time, is high in safety, and is low in side effect when be used as a crude drug. The Cassia fermented by lactic acid bacteria has an effect that more than one of the excrement amount, the moisture content and the excrement weight is increased, the effect is the same as that of a commercial Dulcolax-S with sennoside or bisacodyl and docusate sodium as the active ingredient, the commercial Dulcolax-S is an irritant constipation therapeutic agent and is forbidden to be used for health care foods due to the side effect. Thus, the Cassia fermented by lactic acid bacteria can be applied to pharmaceutical compositions for constipation treatment or prevention, or health care foods for constipation improvement or prevention. Furthermore, the Lactobacilluskefiri MJ90 bacterial strain is beneficial to the preparation of Cassia fermented by lactic acid bacteria for improving treating or preventing constipation.
Owner:HEANAM NATURAL FARMING ASSOC COOPERATION
Colon cleansing composition and method
InactiveUS20060073214A1Large volumeEliminate needOrganic active ingredientsBiocideBisacodylMetoclopramide
A composition and method for cleansing a colon prior to endoscopic procedure. More particularly, a combination of bisacodyl, metoclopramide, sodium, and / or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.
Owner:LONG NECK MEDICAL ENTERPRISES
Novel matrix formula and production method of bisacodyl suppository
InactiveCN104623678ASolve adverse reactions such as abdominal painSolve intolerable problemsOrganic active ingredientsComponent separationBisacodylWater baths
The invention relates to a novel matrix formula and a production method of a bisacodyl suppository, and belongs to the technical field of medicine. According to the novel matrix formula, a greasy matrix is adopted as an accessory and the matrix is mainly formed by use of semisynthetic fatty glycerides. The preparation method of the bisacodyl suppository comprises the following steps: weighing the matrix in a proportion specified in the formula, heating in water bath for melting, and then adding the bisacodyl in a proportion specified in the formula, heating in water bath and stirring for dissolving, and then filling. The matrix of the bisacodyl suppository is used for solving the problem that the existing commercial bisacodyl products in China are possible to cause adverse effects such as stomachache and intolerance to many patients. The stability of the quality of the bisacodyl suppository is greatly improved. The chromatogram of the product utilizing the greasy matrix has no unknown impurity peak.
Owner:药大制药有限公司
Bisacodyl drop pill and preparing method thereof
The present invention utilizes ultramicropulverization and dripping pill preparation production process to make bisacodyl dripping pills, and can attain the goal of raising disintegration and dissolution speed, quickly obtaining therapeutic effect, raising stability of medicine, reducing dose of auxiliary material, reducing production cost and convenient administration. Said pill not only can be sucked, but also can be swallowed, and its compliance property is good.
Owner:HONGYI SCI & TECH CO LTD NANCHANG
Pharmaceutical composition
InactiveUS7704948B2Safe and effectiveGentle laxativeBiocideDispersion deliveryBisacodylEnteric coated
Owner:EURO-CELTIQUE SA
Colon cleansing composition and method
InactiveUS20050064043A1Large volumeEliminate needOrganic active ingredientsBiocideBisacodylMetoclopramide
A composition and method for cleansing a colon prior to endoscopic procedure. More particularly, a combination of bisacodyl, metoclopramide, sodium, and / or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.
Owner:LONG NECK MEDICAL ENTERPRISES
Medicine composition
InactiveCN1476837AObvious excretion effectEliminate rougheningPowder deliveryOrganic active ingredientsBisacodylVitamin
This medicament is a medicinal composition containing bisacodyl, sennoside or its salt and vitamins as effective components, and is used as an aperient for treating constipation.
Owner:SS PHARMA CO LTD
Compound preparation for relaxing bowel and preparation method thereof
InactiveCN109350660APromote peristalsisAvoid side effectsOrganic active ingredientsDigestive systemSide effectDrug withdrawal
The invention discloses a compound preparation for relaxing bowel, relates to the technical field of medicines, and aims at solving the problems of side effects generated by western medicines, repeated drug withdrawal and troublesome traditional Chinese medicine taking. The compound preparation comprises, by weight, 50-60 parts of bisacodyl, 40-50 parts of starch, 0.5-1.5 parts of sodium tripolyphosphate, 20-30 parts of mannitol, 10-20 parts of oligosaccharide, 10-20 parts of honey, 6-12 parts of prune juice, 2-4 parts of compound vitamins and 50-60 parts of traditional Chinese extracts. The invention further discloses a preparation method of the compound preparation for relaxing bowel, a manner of the combination of western and traditional Chinese medicines is adopted, the problem of constipation can be rapidly and effectively solved, bowel can be adjusted to prevent the problems of the side effects caused by the western medicine and repeated drug withdrawal, the oligosaccharide is added, so that the growing of intestinal probiotics is promoted, the growing of harmful bacteria is inhibited, and intestinal microflora is balanced.
Owner:何凤姣
Composition for improvement, treatment or prevention of constipation comprising cassia seed lactic acid bacteria fermented product as effective ingredient, and method for preparing same
InactiveUS20170252392A1Increasing number and water content and weightHigh activityBacteriaDigestive systemSide effectFeces
The present invention relates to a lactic acid fermented product of cassia seeds. The fermented product of the present invention uses cassia seeds, which have long been used and have proven their safety without causing side effects. Due to this advantage, the lactic acid fermented product of the present invention is effective in increasing the number, water content, and / or weight of feces. The effects of the lactic acid fermented product according to the present invention are comparable to those of sennoside, which is a therapeutic agent for stimulant constipation and whose use in health functional foods is forbidden because of its side effects, and Dulcolax-S, which is currently commercially available and includes bisacodyl and sodium docusate as active ingredients. Therefore, the lactic acid fermented product of the present invention can be utilized in pharmaceutical compositions for treating or preventing constipation or health functional foods for ameliorating or preventing constipation. In addition, the present invention relates to Lactobacillus kefiri strain MJ90. The strain is advantageous for the preparation of the lactic acid fermented product with enhanced activity in the treatment, amelioration or prevention of constipation.
Owner:HEANAM NATURAL FARMING ASSOC COOPERATION
Poorly water-soluble drug-containing solid formulation
InactiveUS20070196484A1Improve solubilityGood effectBiocideOrganic active ingredientsBisacodylMedicine
Even when being released in a region from a lower small intestine to a large intestine with various coatings, bisacodyl is inadequately effective because of its hardness to dissolve due to its poor solubility, and thus a more drug should be contained. In the related art, there have been no techniques for allowing bisacodyl and dioctyl sodium sulfosuccinate to be simultaneously released in a region from a lower small intestine to a large intestine. A solid formulation having a core particle containing bisacodyl and dioctyl sodium sulfosuccinate coated with an enteric coating which allows the drugs to be released in a region from a lower small intestine to a large intestine can be used as an excellent pharmaceutical product.
Owner:TAISHO PHARMACEUTICAL CO LTD +1
Methods of administering safe colon cleansing compositions
Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
Owner:AZURITY PHARMA INC
Methods of administering safe colon cleansing compositions
Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
Owner:AZURITY PHARMA INC
Purgative composition for cleansing intestinal tract
InactiveUS20180318234A1High drug complianceSuperior intestinal tract cleansing effectHydroxy compound active ingredientsDigestive systemBisacodylPicosulfate sodium
The present invention relates to a purgative composition for cleansing an intestinal tract and, specifically, to a purgative composition for cleansing an intestinal tract, the composition containing 40-60 g of polyethylene glycol, 10-28 g of sorbitol, and 1-10 mg of sodium picosulfate, on the basis of 100 ml of the composition, or 40-60 g of polyethylene glycol, 10-28 g of sorbitol, and 1-15 mg of bisacodyl, on the basis of 100 ml of the composition. The purgative composition according to the present invention has higher drug compliance while showing an excellent intestinal tract cleansing rate. In addition, the purgative composition exhibits a sufficient intestinal tract cleansing effect even when taken together with a small amount of water, thereby relieving the suffering that a patient must take a large amount of medicine when taking a purgative.
Owner:CTC BIO INC
Preparation method of bisacodyl
Owner:HEBEI KANGTAI PHARMA
Oxyphenisatin acetate, oxyphenisatin and bisacodyl for treating triple-negative breast cancer
The disclosure provides a method of treating triple negative breast cancer in a patient, comprising administering a therapeutically effective amount of a compound selected from oxyphenisatin, oxyphenisatin acetate, and bisacodyl, and the pharmaceutically acceptable salts and hydrates of any of the foregoing to the patient. The disclosure also provides methods of using a compound selected from oxyphenisatin, oxyphenisatin acetate, and bisacodyl, and the pharmaceutically acceptable a salts and hydrates of any of the foregoing, as a first active agent in combination with one or more additional active agents to treat triple negative breast cancer. The disclosure further provides methods for determining whether a patient suffering from triple negative breast cancer would be responsive to treatment with oxyphenisatin, oxyphenisatin acetate, or bisacodyl.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES +2
Methods of administering safe colon cleansing compositions
Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
Owner:AZURITY PHARMA INC
Methods of administering safe colon cleansing compositions
Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
Owner:AZURITY PHARMA INC
Methods of administering safe colon cleansing compositions
Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
Owner:AZURITY PHARMA INC
Novel bisacoridine crystal form as well as preparation and application thereof
The invention belongs to the technical field of pharmaceutical chemistry, and discloses a novel bisacodine crystal form and preparation and application thereof, and an XRPD (X-ray powder diffraction) pattern of the novel bisacodine crystal form has characteristic peaks at the following 2 theta angle positions: 14.40 + / -0.2 degrees, 16.53 + / -0.2 degrees, 17.96 + / -0.2 degrees, 18.93 + / -0.2 degrees, 19.79 + / -0.2 degrees, 21.77 + / -0.2 degrees and 22.37 + / -0.2 degrees. The novel bisacodine crystal form provided by the invention has excellent storage stability and preparation stability, a preparation of the novel bisacodine crystal form can well solve the problems of drug purity decline and the like caused by factors such as temperature and humidity, the risk of curative effect decline is effectively reduced, and the novel bisacodine crystal form is suitable for industrial production and has good economic value and application value.
Owner:HUBEI HONGYUAN PHARMA
Methods of administering safe colon cleansing compositions
Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
Owner:AZURITY PHARMA INC
a weight loss drug
ActiveCN103948591BAccelerate metabolic utilizationShorten absorption timeOrganic active ingredientsMetabolism disorderDiarrheaLost Weight
Owner:温军海
Oral administration of sodium chloride to prevent complications associated with bowel cleansing with stimulant laxatives
PendingUS20220143079A1Prevents unwanted side effectAvoid side effectsPowder deliveryOrganic active ingredientsBowel cleansingSide effect
A method for preventing unwanted side effects associated with the administration stimulant laxative such as bisacodyl or sodium picosulphate by orally administering sodium chloride to the patient is disclosed. Said side effects include hyponatraemia, hypokalemia, unwanted fluctuations in blood pressure, hypotension and renal failure. In certain embodiments, the sodium chloride is administered in the form of tablets during the two hours period following the administration of the stimulant laxative. This method is particularly useful in preparing patients for a colonoscopy.
Owner:SEAFORD PHARMA INC
Use of torreya grandis inner seed coat extract in preparing a product for treating constipation
ActiveCN117982546BDigestive systemConiferophyta medical ingredientsBiotechnologyIntestinal propulsion
The present application provides the application of torreya grandis inner seed coat extract in preparing a product for treating constipation, wherein the torreya grandis inner seed coat extract is obtained by stripping the black coat of torreya grandis after roasting, and then extracting the black coat with water or 50% ethanol, and drying the extract obtained by vacuum concentration; and the prepared torreya grandis inner seed coat extract is used in preparing various dosage forms of drugs for treating constipation and products for lubricating intestines and defecating. The prepared torreya grandis inner seed coat extract powder has the effect of promoting intestinal propulsion, can improve the small intestinal propulsion function, and can achieve good lubricating intestines and defecating effect, and can be used for treating constipation. The torreya grandis inner seed coat powder can be used for preparing food with the effect of lubricating intestines and defecating, so that the function of treating and conditioning constipation can be achieved through diet therapy, and the side effects of the commonly used drugs such as magnesium sulfate, castor oil, cisapride, loperamide, domperidone and bisacodyl can be overcome, and the resource utilization rate of torreya grandis is increased, and the economic benefits are increased.
Owner:TONGLU FEILIUXIANG AGRI DEV CO LTD +1
Methods of administering safe colon cleansing compositions
PCT designated stage expiredWO2024256873A1Dispersion deliveryDigestive systemBowel cleansingBisacodyl
Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.
Owner:SEBELA IRELAND LTD